Transgene S.A.
TNG
Kedudukan dalam Saham
#17522
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Harga Saham
$0.80895783
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$225.10M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-46.22%
Negara
FR
Perdagangan Transgene S.A. (TNG)
Kategori
Healthcare
Modal pasaran bagi Transgene S.A.(TNG)
Modal Pasaran: $225.10M
Sehingga October 2026, Transgene S.A. mempunyai modal pasaran sebanyak $225.10M. Ini menjadikan Transgene S.A. syarikat ke-17522nd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Transgene S.A. dari 2008 hingga 2026
TNG berbanding dengan 5 teratas yang paling popular stocks
